{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 14 of 92', 'CR845-CLIN3103', 'Sensitivity analyses of the primary efficacy endpoint will be conducted', 'to evaluate the robustness of study results under different assumptions', 'and imputation algorithms (Section 8.7.1).', 'Secondary Efficacy Enpoints', 'The proportion of patients achieving >4-point improvement from', 'baseline at Week 12 of the Double-blind Treatment Period, the', 'proportion of patients achieving 3-point improvement from baseline', 'at Week 8 and Week 4, and the proportion of patients achieving >4-', 'point improvement from baseline at Week 8 and Week 4 with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS', 'will be analyzed following a similar methodology to the one employed', 'in the primary analysis of the primary endpoint.', 'The Skindex-10 Scale total score and the 5-D Itch Scale total score', 'change from baseline at Week 12 will be analyzed using an analysis of', 'covariance (ANCOVA) model that contains treatment as fixed effect,', 'with baseline score, region, and the randomization stratification', 'variables as covariates. For each domain in each questionnaire,', 'missing values at Week 12 will be imputed using a MI approach,', 'assuming that patients who discontinue double-blind treatment early', 'would have similar domain scores as other patients in their respective', 'treatment arm that have complete data:', 'Intermittent missing scores will first be imputed using the', 'Markov Chain Monte Carlo (MCMC) method implemented', 'with the SAS MI procedure, which is appropriate for non-', 'monotonic missing data.', 'The monotone missing values will then be multiply imputed', 'with the SAS MI procedure using the monotone regression', 'method.', 'It is important to note that, in HD patients, the study drug administered', 'during the last dialysis of a particular week is not cleared until the first', 'dialysis of the next week. Therefore, measurements that would reflect', 'treatment effect at the end of a specific week (eg. Week 4) will actually', 'be collected during the first day of the next week (eg. Week 5).', 'Hypothesis Testing Strategy', 'Testing of the primary efficacy endpoint will be 2-sided and conducted', 'at the 5% error level. The study will be considered positive if the null', 'hypothesis of no treatment difference in the primary efficacy analysis', 'of the primary endpoint (proportion of patients with a 3-point', 'improvement from baseline at Week 12 of the Double-blind Treatment', 'Period with respect to the Worst Itching Intensity NRS) is rejected in', 'favor of the alternative that patients randomized to CR845 experience', 'significantly less itching compared to patients randomized to placebo.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 15 of 92', 'CR845-CLIN3103', 'To protect the Type 1 error, a gate-keeping strategy will be', 'implemented. Although the p-values corresponding to the hypothesis', 'testing of the secondary variables will be reported, they will only be', 'considered inferential if the primary analysis is statistically significant.', 'Testing of the secondary efficacy endpoints will be performed', 'sequentially at a 2-sided 5% error level in the order specified below. If', 'the test of an endpoint in the sequence is not statistically significant,', 'the p-value for the tests corresponding to the remaining endpoints in', 'the sequence will not be considered inferential and the null hypotheses', 'for the subsequent tests will not be rejected.', '1. Proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 12 of the Double-blind', 'Treatment Period', '2. Proportion of patients achieving 3-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 8 of the Double-blind', 'Treatment Period', '3. Proportion of patients achieving >3-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 4 of the Double-blind', 'Treatment Period', '4. Proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 8 of the Double-blind', 'Treatment Period', '5. Proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 4 of the Double-blind', 'Treatment Period', '6. Change from baseline in Skindex-10 Scale total score at Week', '12 of the Double-blind Treatment Period', '7. Change from baseline in 5-D Itch Scale total score at Week 12', 'of the Double-blind Treatment Period', 'Details and methods of analysis are found in Section 8.0 and will be', 'described further in the statistical analysis plan.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}